FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Murray Epstein

Research Profile

Anatomy

Kidneys

Disorders

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Murray Epstein; Nosratola D Vaziri
Statins in the management of dyslipidemia associated with chronic kidney disease.
Murray Epstein; David A Calhoun
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
James R Sowers; Adam Whaley-Connell; Murray Epstein
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Murray Epstein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Murray Epstein; Nosratola D Vaziri
Statins in the management of dyslipidemia associated with chronic kidney disease.
Nature reviews. Nephrology 2012;8(4):214-23.
2011: Murray Epstein; David A Calhoun
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
Journal of clinical hypertension (Greenwich, Conn.) 2011;13(9):644-8.
2009: James R Sowers; Adam Whaley-Connell; Murray Epstein
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
Annals of internal medicine 2009;150(11):776-83.
2009: Murray Epstein
Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room.
Journal of clinical hypertension (Greenwich, Conn.) 2009;11(2):55-60.
2009: Murray Epstein
John P. Merrill: the father of nephrology as a specialty.
Clinical journal of the American Society of Nephrology : CJASN 2009;4(1):2-8.
2009: Murray Epstein
Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease.
Nature clinical practice. Nephrology 2009;5(1):12-3.
2007: Murray Epstein; David A Calhoun
The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy.
Current hypertension reports 2007;9(2):98-105.
2007: Murray Epstein; Elizabeth Leary; Rachel Laskey; Andrea Zuckerman; David Reed; Wing Lowe
Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.
Journal of the cardiometabolic syndrome 2007;2(3):163-7.
2007: Murray Epstein
Resistant hypertension: prevalence and evolving concepts.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(1 Suppl 1):2-6.
2006: Murray Epstein
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
The American journal of medicine 2006;119(11):912-9.
2006: Norman K Hollenberg; Murray Epstein
Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
Clinical journal of the American Society of Nephrology : CJASN 2006;1(5):1046-8.
2006: Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Clinical journal of the American Society of Nephrology : CJASN 2006;1(5):940-51.
2006: Reinaldo Rosario; Murray Epstein
Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2006;7(3):135-8.
2006: Murray Epstein
Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy.
Nature clinical practice. Nephrology 2006;2(6):310-1.
2006: Murray Epstein; Michel E Safar
Aldosterone and large artery vessels.
Hypertension 2006;47(6):e24; author reply e25.
2005: Vito M Campese; Mitra K Nadim; Murray Epstein
Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
Journal of the American Society of Nephrology : JASN 2005;16 Suppl 1():S11-7.
2005: Murray Epstein; Vito M Campese
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2005;45(1):2-14.
2004: Arif Asif; David L Epstein; Murray Epstein
Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
Journal of clinical pharmacology 2004;44(12):1342-51.
2004: Murray Epstein; Norman K Hollenberg
Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
American journal of hypertension 2004;17(7):638-9; author reply 639-40.
2004: Arif Asif; Murray Epstein
Prevention of radiocontrast-induced nephropathy.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2004;44(1):12-24.
2004: Murray Epstein
Role of aldosterone blockade in the management of hypertension and cardiovascular disease.
Contributions to nephrology 2004;143():90-104.
2004: Murray Epstein; Vito M Campese
Evolving role of calcium antagonists in the management of hypertension.
The Medical clinics of North America 2004;88(1):149-65.
2003: Murray Epstein
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003;18(10):1984-92.
2003: Janice G Douglas; George L Bakris; Murray Epstein; Keith C Ferdinand; Carlos Ferrario; John M Flack; Kenneth A Jamerson; Wendell E Jones; Julian Haywood; Randall Maxey; Elizabeth Ofili; Elijah Saunders; Ernesto L Schiffrin; Domenic A Sica; James R Sowers; Donald G Vidt
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.
Archives of internal medicine 2003;163(5):525-41.
2002: Murray Epstein
Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2002;20(6):S17-23.
2002: Radko Komers; Murray Epstein
Cyclooxygenase-2 expression and function in renal pathophysiology.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2002;20(6):S11-5.
2002: Murray Epstein
Recent landmark clinical trials: how do they modify the therapeutic paradigm?
American journal of hypertension 2002;15(7 Pt 2):82S-84S.
2002: Richard A Preston; Neyton M Baltodano; Alberto B Alonso; Murray Epstein
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus.
Journal of clinical pharmacology 2002;42(7):754-61.
2002: Murray Epstein
Evolving therapeutic strategies for retarding progression of diabetic nephropathy--an update for 2002.
Acta diabetologica 2002;39 Suppl 2():S41-5.
2002: Sheldon Tobe; Murray Epstein
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.
Current hypertension reports 2002;4(3):191-4.
2002: George L Bakris; A C Smith; D J Richardson; E Hung; Richard A Preston; Ronald B Goldberg; Murray Epstein
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
Journal of human hypertension 2002;16(3):185-91.
2001: Radko Komers; Sharon Anderson; Murray Epstein
Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38(6):1145-57.
2001: Murray Epstein
Lercanidipine: a novel dihydropyridine calcium-channel blocker.
Heart disease (Hagerstown, Md.) 2001;3(6):398-407.
2001: Richard A Preston; M Chung; M Gaffney; A Alonso; Neyton M Baltodano; Murray Epstein
Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus.
Journal of clinical pharmacology 2001;41(11):1215-24.
2001: Murray Epstein; S Tobe
What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?
Current hypertension reports 2001;3(5):422-8.
2001: Murray Epstein
Aldosterone as a determinant of cardiovascular and renal dysfunction.
Journal of the Royal Society of Medicine 2001;94(8):378-83.
2001: Murray Epstein
Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives.
Internal medicine (Tokyo, Japan) 2001;40(7):573-83.
2001: Murray Epstein; H R Black
Arterial calcification and calcium antagonists: what does it mean?
Hypertension 2001;37(6):1414-5.
2001: Murray Epstein
Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.
Journal of hypertension 2001;19(5):829-42.
2001: Murray Epstein
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;37(4):677-88.
2001: Murray Epstein
Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.
American journal of therapeutics 2001;8(2):81-3.
2000: G L Bakris; M Williams; L Dworkin; W J Elliott; Murray Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; James R Sowers
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;36(3):646-61.
2000: James R Sowers; M Williams; Murray Epstein; G Bakris
Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications.
Postgraduate medicine 2000;107(4):47-54, 60.
2000: George L Bakris; James R Sowers; Murray Epstein; M Williams
Hypertension in patients with diabetes. Why is aggressive treatment essential?
Postgraduate medicine 2000;107(2):53-6, 61-4.
1999: Vandana Mathur; Suzanne K Swan; Larry Lambrecht; S Anjum; Jere Fellmann; Dawn McGuire; Murray Epstein; Robert R Luther
The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.
Critical care medicine 1999;27(9):1832-7.
1999: Suzanne Oparil; S Aronson; G Michael Deeb; Murray Epstein; J H Levy; R R Luther; R Prielipp; A Taylor
Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises.
American journal of hypertension 1999;12(7):653-64.
1999: Richard A Preston; Murray Epstein
Effects of diabetes on cardiovascular drug metabolism. Emerging clinical implications.
Diabetes care 1999;22(6):982-8.
1999: Murray Epstein
Diagnosis and management of hypertensive emergencies.
Clinical cornerstone 1999;2(1):41-54.
1999: Murray Epstein
Role of a third generation calcium antagonist in the management of hypertension.
Drugs 1999;57 Suppl 1():1-10.
1998: Murray Epstein
Calcium antagonists and renal disease.
Kidney international 1998;54(5):1771-84.
1998: Murray Epstein
Calcium antagonists and renal protection: emerging perspectives.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1998;16(4):S17-25.
1998: Richard A Preston; Murray Epstein
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
American journal of therapeutics 1998;5(3):203-10.
1998: I Singer; Murray Epstein
Potential of dopamine A-1 agonists in the management of acute renal failure.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1998;31(5):743-55.
1998: Murray Epstein
Calcium antagonists and the progression of chronic renal failure.
Current opinion in nephrology and hypertension 1998;7(2):171-6.
1997: Richard A Preston; Murray Epstein
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Journal of hypertension 1997;15(12 Pt 1):1365-77.
1997: Chiyoko N Inoue; Y H Ko; William B Guggino; H G Forster; Murray Epstein
Lysophosphatidic acid and platelet-derived growth factor synergistically stimulate growth of cultured rat mesangial cells.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1997;216(3):370-9.
1997: AA Kaplan; Murray Epstein
Extracorporeal blood purification in the management of patients with hepatic failure.
Seminars in nephrology 1997;17(6):576-82.
1997: Murray Epstein
Hepatorenal syndrome: emerging perspectives.
Seminars in nephrology 1997;17(6):563-75.
1997: Arthur L Bassett; Simon Chakko; Murray Epstein
Are calcium antagonists proarrhythmic?
Journal of hypertension 1997;15(9):915-23.
1997: Massimo Volpe; P Magri; Maria Assunta Elena Rao; S Cangianiello; L DeNicola; AF Mele; Bruno Memoli; I Enea; Speranza Rubattu; Bruna Gigante; Bruno Trimarco; Murray Epstein; Mario Condorelli
Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition.
Hypertension 1997;30(2 Pt 1):168-76.
1997: Murray Epstein
The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk.
The American journal of cardiology 1997;79(10A):9-19; discussion 47-8.
1997: Murray Epstein; M S Goligorsky
Endothelin and nitric oxide in hepatorenal syndrome: a balance reset.
Journal of nephrology 1997;10(3):120-35.
1997: P M ter Wee; H G Forster; Murray Epstein
Video-microscopic assessment of the role of tissue angiotensin-converting enzyme in the control of the renal microcirculation.
The Journal of pharmacology and experimental therapeutics 1997;281(1):434-9.
1997: Murray Epstein
Diabetes and hypertension: the bad companions.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1997;15(2):S55-62.
1997: Pieter A van Zwieten; L Hansson; Murray Epstein
Slowly acting calcium antagonists and their merits.
Blood pressure 1997;6(2):78-80.
1997: Murray Epstein
Alcohol's impact on kidney function.
Alcohol health and research world 1997;21(1):84-92.
1997: Murray Epstein; H H Parving; L M Ruilope
Surrogate endpoints and renal protection: focus on microalbuminuria.
Blood pressure. Supplement 1997;2():52-7.
1997: Murray Epstein
Calcium channel blockers and hypertension: evolving perspective--1996.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1997;10 Suppl 3():883-91.
1997: Koichi Hayashi; R Loutzenhiser; Murray Epstein
Direct evidence that thromboxane mimetic U44069 preferentially constricts the afferent arteriole.
Journal of the American Society of Nephrology : JASN 1997;8(1):25-31.
1996: Murray Epstein
Calcium channel blockers and hypertension: 2. Safety issues.
Hospital practice (1995) 1996;31(12):93-6, 99-104.
1996: Koichi Hayashi; Murray Epstein; Takao Saruta
Altered myogenic responsiveness of the renal microvasculature in experimental hypertension.
Journal of hypertension 1996;14(12):1387-401.
1996: Murray Epstein
The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy.
Renal failure 1996;18(6):813-32.
1996: Murray Epstein; G Bakris
Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy.
Archives of internal medicine 1996;156(17):1969-78.
1996: Murray Epstein
Aging and the kidney.
Journal of the American Society of Nephrology : JASN 1996;7(8):1106-22.
1996: H G Forster; P M ter Wee; T C Hohman; Murray Epstein
Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
Diabetologia 1996;39(8):907-14.
1996: Richard A Preston; I Singer; Murray Epstein
Renal Parenchymal Hypertension: current concepts of pathogenesis and management.
Archives of internal medicine 1996;156(6):602-11.
1996: Koichi Hayashi; Takahiko Nagahama; K Oka; Murray Epstein; Takao Saruta
Disparate effects of calcium antagonists on renal microcirculation.
Hypertension research : official journal of the Japanese Society of Hypertension 1996;19(1):31-6.
1996: Murray Epstein
Calcium antagonists: still appropriate as first line antihypertensive agents.
American journal of hypertension 1996;9(2):110-21.
1996: David L Vesely; Richard A Preston; William R Gower; S Chiou; Murray Epstein
Increased release of kaliuretic peptide during immersion-induced central hypervolemia in cirrhotic humans.
American journal of nephrology 1996;16(2):128-37.
1995: James R Sowers; Murray Epstein
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update.
Hypertension 1995;26(6 Pt 1):869-79.
1995: H L Elliott; Murray Epstein; H Haller; G Mancia
Safety of calcium antagonists.
Lancet 1995;346(8987):1421.
1995: Murray Epstein
Calcium antagonists should continue to be used for first-line treatment of hypertension.
Archives of internal medicine 1995;155(20):2150-6.
1995: Chiyoko N Inoue; H G Forster; Murray Epstein
Effects of lysophosphatidic acid, a novel lipid mediator, on cytosolic Ca2+ and contractility in cultured rat mesangial cells.
Circulation research 1995;77(5):888-96.
1995: Murray Epstein
Renal sodium retention in liver disease.
Hospital practice (1995) 1995;30(9):33-7, 41-2.
1995: Murray Epstein
Evolving concepts in the management of hypertension.
Clinical cardiology 1995;18(6 Suppl 3):III 3-11.
1995: Richard A Preston; Murray Epstein
Renal parenchymal disease and hypertension.
Seminars in nephrology 1995;15(2):138-51.
1995: Murray Epstein
Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.
Blood pressure. Supplement 1995;2():108-12.
1994: Koichi Hayashi; R Loutzenhiser; Murray Epstein; H Suzuki; Takao Saruta
Multiple factors contribute to acetylcholine-induced renal afferent arteriolar vasodilation during myogenic and norepinephrine- and KCl-induced vasoconstriction. Studies in the isolated perfused hydronephrotic kidney.
Circulation research 1994;75(5):821-8.
1994: H G Forster; P M ter Wee; T Takenaka; T C Hohman; Murray Epstein
Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1994;206(4):365-74.
1994: P M ter Wee; A G De Micheli; Murray Epstein
Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease.
Archives of internal medicine 1994;154(11):1185-202.
1994: Murray Epstein
Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy.
Journal of the American Society of Nephrology : JASN 1994;4(10):1735-53.
1994: Murray Epstein
Hypertension as a risk factor for progression of chronic renal disease.
Blood pressure. Supplement 1994;1():23-8.
1994: A G De Micheli; H Forster; Robert Duncan; Murray Epstein
A quantitative assessment of renal blood flow autoregulation in experimental diabetes.
Nephron 1994;68(2):245-51.
1994: Murray Epstein
Calcium antagonists and the kidney.
Journal of cardiovascular pharmacology 1994;24 Suppl A():S18-24.
1993: T Takenaka; H Forster; Murray Epstein
Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin.
Circulation research 1993;73(4):743-50.
1993: P M ter Wee; Murray Epstein
Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease.
Archives of internal medicine 1993;153(15):1749-59.
1993: Murray Epstein
Calcium antagonists and the kidney. Implications for renal protection.
American journal of hypertension 1993;6(7 Pt 2):251S-259S.
1993: Murray Epstein
Calcium antagonists and the kidney: future therapeutic perspectives.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;21(6 Suppl 3):16-25.
1993: L Warner; K Skorecki; L M Blendis; Murray Epstein
Atrial natriuretic factor and liver disease.
Hepatology (Baltimore, Md.) 1993;17(3):500-13.
1993: T Takenaka; H Forster; Murray Epstein
Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435.
The Journal of pharmacology and experimental therapeutics 1993;264(3):1154-9.
1992: T Takenaka; H Forster; A De Micheli; Murray Epstein
Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats.
Circulation research 1992;71(2):471-80.
1992: Murray Epstein
Calcium antagonists and renal protection. Current status and future perspectives.
Archives of internal medicine 1992;152(8):1573-84.
1992: Murray Epstein
Renal effects of head-out water immersion in humans: a 15-year update.
Physiological reviews 1992;72(3):563-621.
1992: T Takenaka; Y Hashimoto; Murray Epstein
Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats.
Journal of the American Society of Nephrology : JASN 1992;3(1):42-50.
1992: A Valdivieso; R Loutzenhiser; Murray Epstein
[Effect of octopamine on arterial pressure and renal function in the normal rat].
Revista médica de Chile 1992;120(7):748-54.
1992: Murray Epstein
Calcium antagonists and the kidney: implications for renal protection.
Kidney international. Supplement 1992;36():S66-72.
1992: K Hayashi; Murray Epstein; R Loutzenhiser; H Forster
Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements.
Journal of the American Society of Nephrology : JASN 1992;2(11):1578-86.
1992: Murray Epstein; James R Sowers
Diabetes mellitus and hypertension.
Hypertension 1992;19(5):403-18.
1992: T Takenaka; Murray Epstein; H Forster; D W Landry; K Iijima; M S Goligorsky
Attenuation of endothelin effects by a chloride channel inhibitor, indanyloxyacetic acid.
The American journal of physiology 1992;262(5 Pt 2):F799-806.
1992: K Hayashi; Murray Epstein; R Loutzenhiser
Enhanced myogenic responsiveness of renal interlobular arteries in spontaneously hypertensive rats.
Hypertension 1992;19(2):153-60.
1992: Murray Epstein; R D Loutzenhiser
Calcium antagonists and the kidney.
The Tohoku journal of experimental medicine 1992;166(1):123-34.
1991: Murray Epstein
Calcium antagonists and renal hemodynamics: implications for renal protection.
Clinical and investigative medicine. Médecine clinique et experimentale 1991;14(6):590-5.
1991: Murray Epstein
Calcium antagonists and diabetic nephropathy.
Archives of internal medicine 1991;151(12):2361-4.
1991: Murray Epstein
Calcium antagonists and renal hemodynamics: implications for renal protection.
Journal of the American Society of Nephrology : JASN 1991;2(2 Suppl 1):S30-6.
1991: J R Oster; Murray Epstein
Use of centrally acting sympatholytic agents in the management of hypertension.
Archives of internal medicine 1991;151(8):1638-44.
1991: Murray Epstein
Calcium antagonists and the kidney. Implications for renal protection.
American journal of hypertension 1991;4(7 Pt 2):482S-486S.
1991: Murray Epstein; R D Loutzenhiser
Renal hemodynamic effects of calcium antagonists: implications for renal transplantation.
Transplantation proceedings 1991;23(2):1775-7.
1991: R Loutzenhiser; Murray Epstein; K Hayashi; T Takenaka; H Forster
Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys.
American journal of hypertension 1991;4(4 Pt 2):309S-314S.
1991: Murray Epstein; David Landsberg
Cyclosporine-induced thrombotic microangiopathy resulting in renal allograft loss and its successful reuse: a report of two cases.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1991;17(3):346-8.
1991: David L Vesely; Richard A Preston; C J Winters; D M Rico; A L Sallman; Murray Epstein
Increased release of the N-terminal and C-terminal portions of the atrial natriuretic factor prohormone during immersion-induced central hypervolemia in cirrhotic humans.
American journal of nephrology 1991;11(3):207-16.
1991: P Norsk; Murray Epstein
Manned space flight and the kidney.
American journal of nephrology 1991;11(2):81-97.
1991: R P Geronemus; N S Schneider; Murray Epstein
Survival in patients treated with continuous arteriovenous hemodialysis for acute renal failure and chronic renal failure. Preliminary observations.
Contributions to nephrology 1991;93():29-31.
1991: Murray Epstein
Diltiazem and renal hemodynamics: implications for renal protection.
Journal of cardiovascular pharmacology 1991;18 Suppl 9():S21-5.
1991: Murray Epstein
Calcium antagonists and the kidney: implications for renal protection.
Journal of cardiovascular pharmacology 1991;18 Suppl 10():S64-70.
1990: Murray Epstein; R D Loutzenhiser
Effects of calcium antagonists on renal hemodynamics.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1990;16(4 Suppl 1):10-4.
1990: R Loutzenhiser; Murray Epstein
Renal microvascular actions of calcium antagonists.
Journal of the American Society of Nephrology : JASN 1990;1(3 Suppl 1):S3-12.
1990: R Loutzenhiser; Y Matsumoto; W Okawa; Murray Epstein
H(+)-induced vasodilation of rat aorta is mediated by alterations in intracellular calcium sequestration.
Circulation research 1990;67(2):426-39.
1990: K Hayashi; Murray Epstein; R Loutzenhiser
Determinants of renal actions of atrial natriuretic peptide. Lack of effect of atrial natriuretic peptide on pressure-induced vasoconstriction.
Circulation research 1990;67(1):1-10.
1990: B Jones; Murray Epstein
Aluminum toxicity in chronic renal failure.
Clinical nephrology 1990;33(5):257.
1990: R Loutzenhiser; Murray Epstein; K Hayashi; C Horton
Direct visualization of effects of endothelin on the renal microvasculature.
The American journal of physiology 1990;258(1 Pt 2):F61-8.
1989: K Hayashi; Murray Epstein; R Loutzenhiser
Pressure-induced vasoconstriction of renal microvessels in normotensive and hypertensive rats. Studies in the isolated perfused hydronephrotic kidney.
Circulation research 1989;65(6):1475-84.
1989: R D Loutzenhiser; Murray Epstein; F Fischetti; C Horton
Effects of amlodipine on renal hemodynamics.
The American journal of cardiology 1989;64(17):122I-127I; discussion 127I-128I.
1989: R Loutzenhiser; K Hayashi; Murray Epstein
Divergent effects of KCl-induced depolarization on afferent and efferent arterioles.
The American journal of physiology 1989;257(4 Pt 2):F561-4.
1989: R D Loutzenhiser; Murray Epstein; K Hayashi
Renal hemodynamic effects of calcium antagonists.
The American journal of cardiology 1989;64(11):41F-45F.
1989: R D Loutzenhiser; Murray Epstein
Calcium antagonists and the kidney.
American journal of hypertension 1989;2(6 Pt 2):154S-161S.
1989: Murray Epstein
The hepatorenal syndrome.
Hospital practice (Office ed.) 1989;24(4):65-76.
1989: G Blyden; F Silverstein; Murray Epstein; P Norsk; B Brenner; N Nwadike; M Dorvil
Lidocaine pharmacokinetics during water immersion in normal humans.
Journal of applied physiology (Bethesda, Md. : 1985) 1989;66(1):57-60.
1989: Murray Epstein
Atrial natriuretic factor in patients with liver disease.
American journal of nephrology 1989;9(2):89-100.
1989: Murray Epstein; R Loutzenhiser; P Norsk; S Atlas
Relationship between plasma ANF responsiveness and renal sodium handling in cirrhotic humans.
American journal of nephrology 1989;9(2):133-43.
1989: Murray Epstein; P Norsk; R Loutzenhiser
Effects of water immersion on atrial natriuretic peptide release in humans.
American journal of nephrology 1989;9(1):1-24.
1988: Robert W Schrier; V Arroyo; M Bernardi; Murray Epstein; J H Henriksen; J Rodés
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology (Baltimore, Md.) 1988;8(5):1151-7.
1988: R Loutzenhiser; K Hayashi; Murray Epstein
Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney.
The Journal of pharmacology and experimental therapeutics 1988;246(2):522-8.
1988: Vicente Arroyo; M Bernardi; Murray Epstein; J H Henriksen; R W Schrier; Juan Rodés
Pathophysiology of ascites and functional renal failure in cirrhosis.
Journal of hepatology 1988;6(2):239-57.
1988: R Loutzenhiser; Murray Epstein
Calcium antagonists and the renal hemodynamic response to vasoconstrictors.
Annals of the New York Academy of Sciences 1988;522():771-84.
1988: P Norsk; Murray Epstein
Effects of water immersion on arginine vasopressin release in humans.
Journal of applied physiology (Bethesda, Md. : 1985) 1988;64(1):1-10.
1988: J R Oster; Murray Epstein
Management of magnesium depletion.
American journal of nephrology 1988;8(5):349-54.
1988: R D Loutzenhiser; Murray Epstein
Renal hemodynamic effects of calcium antagonists.
Journal of cardiovascular pharmacology 1988;12 Suppl 6():S48-52.
1987: Murray Epstein; M Lifschitz
Renal eicosanoids as determinants of renal function in liver disease.
Hepatology (Baltimore, Md.) 1987;7(6):1359-67.
1987: J R Oster; Murray Epstein
Fixed-dose combination medications for the treatment of hypertension: a critical review.
Journal of clinical hypertension 1987;3(3):278-93.
1987: Murray Epstein; P Norsk; R Loutzenhiser; P Sonke
Detailed characterization of a tank used for head-out water immersion in humans.
Journal of applied physiology (Bethesda, Md. : 1985) 1987;63(2):869-71.
1987: R D Loutzenhiser; Murray Epstein
Renal hemodynamic effects of calcium antagonists.
The American journal of medicine 1987;82(3B):23-8.
1987: Murray Epstein; R Loutzenhiser; E Friedland; R M Aceto; M J Camargo; S A Atlas
Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans.
The Journal of clinical investigation 1987;79(3):738-45.
1987: R Loutzenhiser; Murray Epstein; C Horton
Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused rat kidney.
The American journal of cardiology 1987;59(2):72A-75A.
1987: R Loutzenhiser; Murray Epstein
Calcium antagonists and the kidney.
Hospital practice (Office ed.) 1987;22(1):63-76.
1987: R Loutzenhiser; Murray Epstein
Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists.
American journal of nephrology 1987;7 Suppl 1():7-16.
1987: Murray Epstein
The hepatorenal syndrome (HRS).
Advances in experimental medicine and biology 1987;212():157-65.
1987: R Loutzenhiser; Murray Epstein; C Horton
Modification by dihydropyridine-type calcium antagonists of the renal hemodynamic response to vasoconstrictors.
Journal of cardiovascular pharmacology 1987;9 Suppl 1():S70-5.
1986: Murray Epstein
Targeting antihypertensive therapy to the individual patient.
Journal of clinical hypertension 1986;2(3 Suppl):62S-71S.
1986: Murray Epstein; R D Loutzenhiser; E Friedland; R M Aceto; M J Camargo; S A Atlas
Increases in circulating atrial natriuretic factor during immersion-induced central hypervolaemia in normal humans.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1986;4(2):S93-9.
1986: Murray Epstein; R Loutzenhiser; R Levinson
Spectrum of deranged sodium homeostasis in essential hypertension.
Hypertension 1986;8(5):422-32.
1986: R Loutzenhiser; Murray Epstein; C Horton; P Sonke
Reversal of renal and smooth muscle actions of the thromboxane mimetic U-44069 by diltiazem.
The American journal of physiology 1986;250(4 Pt 2):F619-26.
1986: Murray Epstein
The sodium retention of cirrhosis: a reappraisal.
Hepatology (Baltimore, Md.) 1986;6(2):312-5.
1986: Murray Epstein
Renal prostaglandins and the control of renal function in liver disease.
The American journal of medicine 1986;80(1A):46-55.
1985: Murray Epstein
Derangements of renal water handling in liver disease.
Gastroenterology 1985;89(6):1415-25.
1985: R Loutzenhiser; Murray Epstein
Effects of calcium antagonists on renal hemodynamics.
The American journal of physiology 1985;249(5 Pt 2):F619-29.
1985: R Loutzenhiser; Murray Epstein; C Horton; R Hamburger
Nitrendipine-induced stimulation of renin release by the isolated perfused rat kidney.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1985;180(1):133-6.
1985: Murray Epstein
Aging and the kidney: clinical implications.
American family physician 1985;31(4):123-37.
1985: Murray Epstein; J R Oster
Beta blockers and renal function: a reappraisal.
Journal of clinical hypertension 1985;1(1):85-99.
1985: M D Lifschitz; Murray Epstein; O Larios
Relationship between urine flow rate and prostaglandin E excretion in human beings.
The Journal of laboratory and clinical medicine 1985;105(2):234-8.
1985: R Loutzenhiser; Murray Epstein; C Horton; P Sonke
Reversal by the calcium antagonist nisoldipine of norepinephrine-induced reduction of GFR: evidence for preferential antagonism of preglomerular vasoconstriction.
The Journal of pharmacology and experimental therapeutics 1985;232(2):382-7.
1985: Murray Epstein; J R Oster; N K Hollenberg
Beta-blockers and the kidney: implications for renal function and renin release.
The Physiologist 1985;28(1):53-63.
1985: R Loutzenhiser; C Horton; Murray Epstein
Effects of diltiazem and manganese renal hemodynamics: studies in the isolated perfused rat kidney.
Nephron 1985;39(4):382-8.
1985: Murray Epstein; O Larios; G Johnson
Effects of water immersion on plasma catecholamines in decompensated cirrhosis. Implications for deranged sodium and water homeostasis.
Mineral and electrolyte metabolism 1985;11(1):25-34.
1984: R Loutzenhiser; Murray Epstein
Activation mechanisms of human renal artery: effects of KCl, norepinephrine and nitrendipine upon tension development and 45Ca influx.
European journal of pharmacology 1984;106(1):47-52.
1984: Murray Epstein
Water immersion and the kidney: implications for volume regulation.
Undersea biomedical research 1984;11(2):113-21.
1984: Murray Epstein
Renal, endocrine and hemodynamic effects of water immersion in man.
Contributions to nephrology 1984;41():174-88.
1984: J R Oster; Murray Epstein
Acid-base aspects of ketoacidosis.
American journal of nephrology 1984;4(3):137-51.
1984: Murray Epstein; R E Weitzman; S Preston; A G DeNunzio
Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis.
Mineral and electrolyte metabolism 1984;10(3):155-65.
1983: Murray Epstein
Pathogenesis of renal sodium handling in cirrhosis. A reappraisal.
American journal of nephrology 1983;3(6):297-309.
1983: J R Oster; Murray Epstein; S Smoller
Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention.
Annals of internal medicine 1983;99(3):405-6.
1983: Murray Epstein; D Hoffman; A G DeNunzio
Evidence for operation of the magnification phenomenon in patients with chronic renal insufficiency.
Mineral and electrolyte metabolism 1983;9(2):62-8.
1983: Murray Epstein; G Johnson; A G DeNunzio
Effects of water immersion on plasma catecholamines in normal humans.
Journal of applied physiology: respiratory, environmental and exercise physiology 1983;54(1):244-8.
1982: R Loutzenhiser; C Horton; Murray Epstein
Flow-induced errors in estimating perfusion pressure of the isolated rat kidney.
Kidney international 1982;22(6):693-6.
1982: Murray Epstein; M Lifschitz; M Ramachandran; K Rappaport
Characterization of renal prostaglandin E responsiveness in decompensated cirrhosis: implications for renal sodium handling.
Clinical science (London, England : 1979) 1982;63(6):555-63.
1982: Murray Epstein; J R Oster
Beta-blockers and the kidney.
Mineral and electrolyte metabolism 1982;8(5):237-54.
1982: Murray Epstein; M Ramachandran; A G DeNunzio
Interrelationship of renal sodium and phosphate handling in cirrhosis.
Mineral and electrolyte metabolism 1982;7(6):305-15.
1981: Murray Epstein; A G DeNunzio; R D Loutzenhiser
Effects of vasopressin administration on diuresis of water immersion in normal humans.
Journal of applied physiology: respiratory, environmental and exercise physiology 1981;51(6):1384-7.
1981: Murray Epstein
Natriuretic hormone and the sodium retention of cirrhosis.
Gastroenterology 1981;81(2):395-7.
1981: Murray Epstein; S Preston; R E Weitzman
Isoosmotic central blood volume expansion suppresses plasma arginine vasopressin in normal man.
The Journal of clinical endocrinology and metabolism 1981;52(2):256-62.
1981: G O Perez; Murray Epstein; B Rietberg; C Horton
Functional adaptation to reduction in renal mass: renal handling of amino acids by isolated perfused remnant rat kidneys.
Renal physiology 1981;4(4):157-64.
1981: Murray Epstein
The hepatorenal syndrome pathogenesis and prevention.
Clinical and experimental dialysis and apheresis 1981;5(1-2):111-25.
1980: Murray Epstein; A G DeNunzio; M Ramachandran
Characterization of renal response to prolonged immersion in normal man.
Journal of applied physiology: respiratory, environmental and exercise physiology 1980;49(2):184-8.
1980: G Perez; Murray Epstein; B Reitberg; C Horton; R Loutzenhiser
Uptake and release of amino acids by normal and remnant kidneys: studies in the isolated perfused rat kidney.
The American journal of clinical nutrition 1980;33(7):1373-7.
1980: Murray Epstein; M D Lifschitz; R Re; E Haber
Dissociation of renin--aldosterone and renal prostaglandin E during volume expansion induced by immersion in normal man.
Clinical science (London, England : 1979) 1980;59(1):55-62.
1980: Murray Epstein; M D Lifschitz
Volume status as a determinant of the influence of renal PGE on renal function.
Nephron 1980;25(4):157-9.
1980: Murray Epstein; R A Stone; A G DeNunzio; R P Frigon
Relationship between urinary kallikrein and renal sodium handling during water immersion in normal man.
The Journal of clinical endocrinology and metabolism 1980;50(1):122-7.
1980: Murray Epstein
Determinants of abnormal renal sodium handling in cirrhosis: a reappraisal.
Scandinavian journal of clinical and laboratory investigation 1980;40(8):689-94.
1979: L C Martin; J W Ryan; G H Fisher; A Chung; Murray Epstein; J M Stewart
Fate of bradykinin-potentiating peptide 9a after intravenous injection.
The Biochemical journal 1979;184(3):713-6.
1979: Murray Epstein; R Re; S Preston; E Haber
Comparison of the suppressive effects of water immersion and saline administration on renin-aldosterone in normal man.
The Journal of clinical endocrinology and metabolism 1979;49(3):358-63.
1979: Murray Epstein; M D Lifschitz; D S Hoffman; J H Stein
Relationship between renal prostaglandin E and renal sodium handling during water immersion in normal man.
Circulation research 1979;45(1):71-80.
1979: Murray Epstein
Effects of aging on the kidney.
Federation proceedings 1979;38(2):168-71.
1979: Murray Epstein; N K Hollenberg
Renal 'salt wasting' despite apparently normal renal, adrenal and central nervous system function.
Nephron 1979;24(3):121-6.
1979: Murray Epstein
Renal sodium handling in cirrhosis: a reappraisal.
Nephron 1979;23(5):211-7.
1978: N S Bricker; Leon Fine; M Kaplan; Murray Epstein; J J Bourgoignie; A Light
"Magnification phenomenon" in chronic renal disease.
The New England journal of medicine 1978;299(23):1287-93.
1978: G O Perez; Murray Epstein; B Rietberg; R Loutzenhiser
Metabolism of arginine by the isolated perfused rat kidney.
The American journal of physiology 1978;235(4):F376-80.
1978: Murray Epstein
Renal effects of head-out water immersion in man: implications for an understanding of volume homeostasis.
Physiological reviews 1978;58(3):529-81.
1978: N Brautbar; J Levi; A Rosler; E Leitesdorf; M Djaldeti; Murray Epstein; C R Kleeman
Familial hyperkalemia, hypertension, and hyporeninemia with normal aldosterone levels. A tubular defect in potassium handling.
Archives of internal medicine 1978;138(4):607-10.
1978: Murray Epstein; J Sancho; G Perez; E Haber; R Re; R Loutzenhiser
Volume as a determinant of plasma aldosterone in anephric man.
The Journal of clinical endocrinology and metabolism 1978;46(2):309-16.
1978: Murray Epstein; N S Bricker; J J Bourgoignie
Presence of a natriuretic factor in urine of normal men undergoing water immersion.
Kidney international 1978;13(2):152-8.
1978: Murray Epstein
Studies of volume homeostasis in man utilizing the model of head-out water immersion.
Nephron 1978;22(1-3):9-19.
1977: Murray Epstein; R Levinson; J Sancho; E Haber; R Re
Characterization of the renin-aldosterone system in decompensated cirrhosis.
Circulation research 1977;41(6):818-29.
1977: R Sonneborn; G O Perez; Murray Epstein; O Martelo; Victoriano Pardo
Erythrocytosis associated with the nephrotic syndrome.
Archives of internal medicine 1977;137(8):1068-72.
1977: R Levinson; Murray Epstein; M A Sackner; R Begin
Comparison of the effects of water immersion and saline infusion on central haemodynamics in man.
Clinical science and molecular medicine 1977;52(4):343-50.
1977: J R Oster; Murray Epstein
Demeclocycline-induced renal failure.
Lancet 1977;1(8001):52.
1976: J R Oster; Murray Epstein; H B Ulano
Deterioration of renal function with demeclocycline administration.
Current therapeutic research, clinical and experimental 1976;20(6):794-801.
1976: Murray Epstein
Cardiovascular and renal effects of head-out water immersion in man: application of the model in the assessment of volume homeostasis.
Circulation research 1976;39(5):619-28.
1976: Murray Epstein; R Levinson; R Loutzenhiser
Effects of water immersion on renal hemodynamics in normal man.
Journal of applied physiology 1976;41(2):230-3.
1976: Murray Epstein; D S Pins; N Schneider; R Levinson
Determinants of deranged sodium and water homeostasis in decompensated cirrhosis.
The Journal of laboratory and clinical medicine 1976;87(5):822-39.
1976: Murray Epstein; J R Oster; R E de Velasco
Hepatorenal syndrome following hemihepatectomy.
Clinical nephrology 1976;5(3):129-33.
1976: Murray Epstein; N K Hollenberg
Age as a determinant of renal sodium conservation in normal man.
The Journal of laboratory and clinical medicine 1976;87(3):411-7.
1976: Murray Epstein; D S Pins; W Silvers; R Loutzenhiser; J M Canterbury; E Reiss
Failure of water immersion to influence parathyroid hormone secretion and renal phosphate handling in normal man.
The Journal of laboratory and clinical medicine 1976;87(2):218-26.
1975: Murray Epstein; D S Pins; J Sancho; E Haber
Suppression of plasma renin and plasma aldosterone during water immersion in normal man.
The Journal of clinical endocrinology and metabolism 1975;41(3):618-25.
1975: Murray Epstein; D S Pins; R Arrington; A G Denunzio; R Engstrom
Comparison of water immersion and saline infusion as a means of inducing volume expansion in man.
Journal of applied physiology 1975;39(1):66-70.
1975: Murray Epstein; D S Pins; Myron Miller
Suppression of ADH during water immersion in normal man.
Journal of applied physiology 1975;38(6):1038-44.
1975: Murray Epstein; N S Schneider; B Befeler
Effect of intrarenal furosemide on renal function and intratenal hemodynamics in acute renal failure.
The American journal of medicine 1975;58(4):510-6.
1974: Murray Epstein; Myron Miller; N Schneider
Depth of immersion as a determinant of the natriuresis of water immersion.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1974;146(2):562-6.
1974: S J Shubrooks; Murray Epstein; D C Duncan
Effects of an anti-G suit on the hemodynamic and renal responses to positive (+Gz) acceleration.
Journal of applied physiology 1974;36(3):345-9.
1974: Murray Epstein; S J Shubrooks; L M Fishman; D C Duncan
Effects of positive acceleration (+Gz) on renal function and plasma renin in normal man.
Journal of applied physiology 1974;36(3):340-4.
1973: Murray Epstein; J L Katsikas; D C Duncan
Role of mineralocorticoids in the natriuresis of water immersion in man.
Circulation research 1973;32(2):228-36.
1973: J P Hayslett; L M Jampol; J N Forrest; Murray Epstein; H V Murdaugh; J D Myers
Role of Na-K-ATPase in the renal reabsorption of sodium in the elasmobranch, Squalus acanthias.
Comparative biochemistry and physiology. A, Comparative physiology 1973;44(2):417-22.
1973: Murray Epstein; D C Duncan; B E Meek
The role of posture in the natriuresis of water immersion in normal man.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1973;142(1):124-7.
1973: Murray Epstein; T Saruta
Effects of an hyperoxic hypobaric environment on renin-aldosterone in normal man.
Journal of applied physiology 1973;34(1):49-52.
1972: J P Hayslett; Murray Epstein; David A Spector; J D Myers; H V Murdaugh
Lack of effect of calcitonin on renal function in the elasmobranch, Squalus acanthias.
Comparative biochemistry and physiology. A, Comparative physiology 1972;43(1):223-6.
1972: Murray Epstein; T Saruta
Effects of simulated high altitude on renin-aldosterone and Na homeostasis in normal man.
Journal of applied physiology 1972;33(2):204-10.
1972: Murray Epstein; D C Duncan; L M Fishman
Characterization of the natriuresis caused in normal man by immersion in water.
Clinical science 1972;43(2):275-87.
1971: Murray Epstein; L M Fishman; H B Hale; W H Hulet
Dissociation of aldosterone and 17-hydroxycorticosteroid (17-OHCS) release during water immersion in normal man.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1971;138(3):939-42.
1971: Murray Epstein; T Saruta
Effect of water immersion on renin-aldosterone and renal sodium handling in normal man.
Journal of applied physiology 1971;31(3):368-74.
1971: N K Hollenberg; D F Adams; A Rashid; Murray Epstein; H L Abrams; J P Merrill
Renal vascular response to salt restriction in normal man. Evidence against adrenergic mediation.
Circulation 1971;43(6):845-51.
1970: Murray Epstein; D P Berk; N K Hollenberg; D F Adams; T C Chalmers; H L Abrams; J P Merrill
Renal failure in the patient with cirrhosis. The role of active vasoconstriction.
The American journal of medicine 1970;49(2):175-85.
1970: N K Hollenberg; Murray Epstein; R D Guttmann; M Conroy; R I Basch; J P Merrill
Effect of sodium balance on intrarenal distribution of blood flow in normal man.
Journal of applied physiology 1970;28(3):312-7.